Latest Insider Transactions at Immunovant, Inc. (IMVT)
This section provides a real-time view of insider transactions for Immunovant, Inc. (IMVT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunovant, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunovant, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2021
|
Douglas J. Hughes Director |
BUY
Open market or private purchase
|
Direct |
18,247
+23.79%
|
$145,976
$8.24 P/Share
|
|
Aug 20
2021
|
George V Migausky Director |
BUY
Open market or private purchase
|
Direct |
7,000
+9.43%
|
$49,000
$7.65 P/Share
|
|
Aug 13
2021
|
Atul Pande Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+9.96%
|
$35,000
$7.98 P/Share
|
|
Aug 10
2021
|
Andrew J. Fromkin Director |
BUY
Open market or private purchase
|
Direct |
5,500
+10.74%
|
$38,500
$7.9 P/Share
|
|
Aug 03
2021
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
570,613
+44.8%
|
-
|
|
Aug 03
2021
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
285,306
+45.28%
|
-
|
|
Aug 02
2021
|
Roivant Sciences Ltd. |
BUY
Other acquisition or disposition
|
Direct |
17,021,276
+18.83%
|
-
|
|
Jun 11
2021
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,045
+47.73%
|
-
|
|
Mar 19
2021
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,500
+47.81%
|
-
|
|
Mar 19
2021
|
Rita Jain Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,365
+45.81%
|
-
|
|
Mar 19
2021
|
Michael James Elliott Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,600
+50.0%
|
-
|
|
Mar 19
2021
|
Connealy Pamela Yanchik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,200
+50.0%
|
-
|
|
Mar 19
2021
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
132,500
+50.0%
|
-
|
|
Mar 19
2021
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.83%
|
-
|
|
Mar 19
2021
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.83%
|
-
|
|
Mar 19
2021
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.83%
|
-
|
|
Mar 19
2021
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,200
+28.74%
|
-
|
|
Mar 19
2021
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+20.48%
|
-
|
|
Jan 22
2021
|
Rita Jain Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|